Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed…
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab)…
Read More...
Read More...
